3D Printing ROI: Pharmaceutical company sees 95% part cost reduction, 70% weight reduction

In a new case study, global 3D printing leader Stratasys, which will soon introduce its new metal 3D printer, has explained how a top French pharmaceutical company was able to achieve a full return on investment (ROI) within just one year of purchasing and installing one of its production FDM 3D printers.

Bristol-Myers Squibb subsidiary UPSA determined that additive manufacturing would be a good way to attract new technicians, along with putting some life back into its in-house workshop. The company also realized that 3D printing would be able to help it find innovative solutions to production-line challenges, which were limiting the amount of machine parts it could make with traditional methods of manufacturing.

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.